You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 298 No. 8, August 22/29, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Renal Diseases
 •Dialysis
 •Drug Therapy, Other
 •Anemias
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Epoetin Dosing and Dialysis Facility Ownership—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Regidor and colleagues suggest that their observational data1 are similar to clinical trial results. Figure 1 of their study1 shows the adjusted relative hazard ratio of death is approximately 1.5 when the hemoglobin level is 10.0 g/dL vs 1.0 when the hemoglobin level is 13.0 g/dL, while the largest dialysis anemia trial achieving those mean values found a 22% higher relative risk of death from a higher hemoglobin level.2 The study by Regidor et al1 also shows that the hazard ratio of death decreases from approximately 1.4 when the hemoglobin level is 10.0 g/dL to 11.0 g/dL to approximately 0.9 when the hemoglobin level is near 12.0 g/dL. However, actual adjusted mortality among US dialysis patients has not changed, although the mean hemoglobin level has steadily increased from 10 g/dL in 1993 to 12.0 g/dL in 2004.3

Regidor et al1 examined achieved hemoglobin values, yet the writers . . . [Full Text of this Article]

Daniel W. Coyne, MD
dcoyne@im.wustl.edu
Department of Medicine
Washington University School of Medicine
St Louis, Missouri



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED LETTERS

Epoetin Dosing and Dialysis Facility Ownership
Alan S. Kliger and Allen R. Nissenson
JAMA. 2007;298(8):861-862.
EXTRACT | FULL TEXT  

Epoetin Dosing and Dialysis Facility Ownership
Deborah L. Regidor, Kamyar Kalantar-Zadeh, and Csaba P. Kovesdy
JAMA. 2007;298(8):862.
EXTRACT | FULL TEXT  

Epoetin Dosing and Dialysis Facility Ownership—Reply
Mae Thamer, Yi Zhang, Dennis J. Cotter, James Kaufman, and Miguel A. Hernán
JAMA. 2007;298(8):862.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Dialysis Facility Ownership and Epoetin Dosing in Patients Receiving Hemodialysis
Mae Thamer, Yi Zhang, James Kaufman, Dennis Cotter, Fan Dong, and Miguel A. Hernán
JAMA. 2007;297(15):1667-1674.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.